Reflections from the life experiences of patients with Familial Chylomicronemia Syndrome

Reflections from the life experiences of patients with Familial Chylomicronemia Syndrome

A Million-Greenback Illness with a Million-Greenback Remedy

Many individuals imagine their associate is one in 1,000,000, which I discovered when he first shared with me that mine was unable to eat fats resulting from Familial chylomicronemia syndrome (FCS), often known as Lipoprotein Lipase Deficiency (LPLD). A uncommon recessive genetic dysfunction characterised by uncontrollable excessive triglyceride ranges, leading to doubtlessly life-threatening recurrent pancreatitis and problems requiring hospitalization (1,2). Though hypertriglyceridemia is frequent, FCS happens early in life with considerably extra extreme hypertriglyceridemia and long-term sequelae with out efficient therapy.

The prevalence of FCS is estimated to be 1 in 100,000 – 1,000,000 (1,2). Sadly, 48% of FCS sufferers report being misdiagnosed (3). The shortage of worldwide consciousness of FCS enormously contributes to affected person morbidity. General, there’s a vital adverse influence on the bodily, cognitive, and emotional domains related to the illness (3)(4), and entry to care varies by area.

Entry to Analysis, Price, and Well being Care Techniques and Restricted Therapy Choices

Standard pharmacotherapy for hypertriglyceridemia has little or no profit for FCS (2,5,6). Even when they adhere to a really restricted weight loss program, sufferers proceed to expertise pancreatitis and poor high quality of life (3.5), inflicting sufferers to really feel defeated. Glybera, the world’s first authorised gene remedy with a value of 1 million {dollars}, has been authorised for FCS in Europe. uniQure by no means sought FDA approval, and an efficient therapy abruptly disappeared (7-9). Whereas the EU authorised Volanesorsen in 2019, there are not any authorised remedies in North America (10,11). Regardless of approval, only some sufferers obtain therapy. Uncommon ailments, the place many sufferers know extra about their illness than the individuals who deal with them, needs to be extra patient-centred and contain collaborative decision-making in therapy.

Case Research Sequence: Identical illness, completely different experiences exterior the oceans

My husband has struggled with recurrent assaults of acute pancreatitis since childhood. she was informed “I am making it up” Typically. He was recognized with FCS at age 13 when he was genetically examined. The one administration was a weight loss program restricted to boiled greens and low-fat proteins for years. In his youth, he began supplementing with MCT oil, which has positively impacted his psychological well being as he can now take pleasure in a greater diversity of meals. Sadly, he continued to expertise painful assaults of pancreatitis, and plenty of visits to the emergency room have been denied hours of analgesia. My husband, like many FCS sufferers who now keep away from searching for emergency look after AP, was falsely accused of being “drug-seeking” and/or “alcoholic” by HCPs earlier than it grew to become clear that hypertriglyceridemia was the trigger.

We have been enthusiastic about gene remedy, and we felt hopeless the second it was discontinued after a single million-dollar sale. We have been wanting ahead to Volanesorsen, the one drug obtainable in the marketplace that confirmed vital reductions in triglycerides with no different therapy. Volanesorsen was rejected by the FDA resulting from thrombocytopenia considerations. Given the burden of the illness and absolutely the worry that sufferers and their households have of the subsequent assault, we’d have made a acutely aware alternative to observe platelet ranges slightly than search therapy in any respect.

Via the FCS basis within the US and Motion FCS within the UK, I’ve the privilege of assembly a number of FCS sufferers and reflecting on the experiences they’ve boldly shared with me.

A younger US girl, each a affected person and an advocate for FCS, shares that entry to therapy has been a continuing supply of stress and has brought on vital nervousness all through her life. “I need to get excited after I hear a few new drug however I’ve to be real looking that it could not work and in some circumstances it could by no means be authorised and might not be appropriate for long run use.” She struggles to remain constructive, worries that there’ll by no means be a therapy that absolutely works, and lives in fixed worry of getting pancreatitis and long-term well being issues.

He expressed disappointment with the FDA’s choice on Volnesorsen.. “The FDA appears to have little understanding of what FCS sufferers cope with each day. It could be life-changing for sufferers like me who’ve had a number of episodes of pancreatitis.”. It displays the emotions of those that have entry in different nations.

A younger girl with FCS from the UK struggled extraordinarily throughout her being pregnant, a typical expertise for girls with FCS. Regardless of being a clinician herself, her persistent requests for plasmapheresis have been denied till her twenty second week of being pregnant when she was admitted to the intensive care unit. She struggled with emotions of loneliness, despair, nervousness, and worry for herself and her unborn kid’s life. She felt insecure and misplaced her belief within the medical group.

Entry to Volanesorsen adjustments his life for her. “I’ve by no means been in a spot thus far or meet somebody earlier than. I actually did not care to exist anymore”. Lower than a yr after receiving therapy, she felt higher, not wanted a sick depart, met her husband, and was lastly in a position to take a trip with out undue fear about her weight loss program or the standard of care obtainable in an emergency anyplace on this planet. “I do not assume I would be right here with out him. I can really feel regular”.

An aged affected person from England, who spent most of his life with out therapy, largely displays adverse experiences and the patriarchal method of docs. As an advocate for a greater drug approval course of, she shared:What I have not heard of is the affected person’s experiences. They give thought to information, figures and numbers. The essential factor just isn’t how the affected person is, solely the numbers.”feeling annoyed and remoted all through life.

Many sufferers shared their frustration with the shortage of empathy ensuing from restricted understanding of how FCS impacts sufferers’ general well being, work, relationships, and talent to guide a traditional life. A standard concern is that sufferers’ voices are usually not heard when drug approval choices with life-changing implications are made. When efficient medicine with doubtlessly traceable uncomfortable side effects are usually not authorised, affected person autonomy and option to make knowledgeable choices are misplaced. The variables that decide profit and danger ignore the standard of life and the psychosocial burden of the illness. “The one factor they saved was the variety of pancreatitis assaults and hospitalizations.” shared by a number of sufferers. Assets could be directed in direction of understanding the acute problems which are long-term sequelae for a lot of FCS sufferers and the numerous influence of managing continual ailments on day by day life, incapacity, larger danger and prices.


  1. Drone JS, Hegele RA. Genetics of hypertriglyceridemia. Anterior Endocrinol (Lausanne). 2020 July 24;11:455.
  2. Brahm AJ, Hegele RA. Chylomicronemia—present prognosis and future remedies. Nature Opinions Endocrinology 2015 11:6 [Internet]. March 3, 2015 [cited 2022 Oct 22];11(6):352–62. Obtainable at:
  3. Davidson M, Stevenson M, Hsieh A, Ahmad Z, Roeters van Lennep J, Crowson C et al. Burden of familial chylomicronemia syndrome: outcomes of the worldwide IN-FOCUS research. J Clin Lipidol. 2018 Jul 1;12(4):898-907.e2.
  4. Gaudet D, Stevenson M, Komari N, Trentin G, Crowson C, Hadker N, et al. Burden of familial chylomicronemia syndrome in Canadian sufferers. Lipids Well being Dis [Internet]. 2020 June 2 [cited 2022 Nov 8];19(1):1–13. Obtainable at:
  5. Goldberg RB, Chait A. A Complete Replace on Chylomicronemia Syndrome. Anterior Endocrinol (Lausanne). 2020 Oct 23;11:830.
  6. Baass A, Paquette M, Bernard S, Hegele RA. Familial chylomicronemia syndrome: an underrecognized reason behind extreme hypertriglyceridemia. J Intern Med [Internet]. 2020 Apr 1 [cited 2022 Oct 22];287(4):340–8. Obtainable at:
  7. Canadian invention that grew to become the world’s most costly drug after which disappeared will get a second likelihood | CBC Information [Internet]. [cited 2022 Oct 23]. Obtainable at: being/glybera-lpld-rare-drug-orphan-disease-nrc-cbc-price-1.5312177
  8. Han X, Ni W. Price-Effectiveness Evaluation of Glybera within the Therapy of Lipoprotein Lipase Deficiency. Worth in Well being [Internet]. 2015 November 1 [cited 2022 Nov 14];18(7):A756. Obtainable at:
  9. Scott LJ Alipogene tiparvovec: a assessment of its use in adults with familial lipoprotein lipase deficiency. Medicines [Internet]. 2015 [cited 2022 Nov 14];75(2):175–82. Obtainable at:
  10. Paik J, Duggan S. Volanesorsen: First World Affirmation. Medicines [Internet]. 2019 Aug 1 [cited 2022 Nov 12];79(12):1349–54. Obtainable at:
  11. Rossi GP, Benaiges Boix D, Kolovou G, Kolovou V, Katsiki N. Volanesorsen: A New Period within the Therapy of Extreme Hypertriglyceridemia. Journal of Medical Drugs 2022, Vol. 11, Web page 982 [Internet]. 2022 February 13 [cited 2022 Nov 14];11(4):982. Obtainable at:

#Reflections #life #experiences #sufferers #Familial #Chylomicronemia #Syndrome

Leave a Reply

Your email address will not be published. Required fields are marked *